Skip to content

Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Comparison of Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Clinical Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05988671
Enrollment
120
Registered
2023-08-14
Start date
2023-08-10
Completion date
2024-08-30
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy, Postoperative Nausea and Vomiting

Brief summary

Nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postop-erative pain. The double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.

Interventions

DRUGDexmedetomidine

Intraperitoneal route

DRUGCombination of dexamethasone + dexmedetomidine

Intraperitoneal route

DRUGnormal Saline

Intraperitoneal route

DRUGDexamethasone

Intraperitoneal route

Sponsors

Benha University
CollaboratorOTHER
Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged from 20 - 50 years * ASA I OR II * undergo laparoscopic cholecystectomy

Exclusion criteria

* Patients with history of psychotic illnesses, * Parkinson's disease * motion disorder * Smoker * or history of chemotherapy

Design outcomes

Primary

MeasureTime frame
The number of patients suffered from postoperative nausea and vomiting will be recorded in each group.24 hours postoperative

Secondary

MeasureTime frameDescription
antiemetic consumption24 hours postoperativelyfrequency of antiemetic consumption will be determined

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026